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BACKGROUND & AIMS: Patients with Crohn’s disease (CD), but not ulcerative colitis (UC), of shorter duration have higher
rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease
duration. Little is known about the association between disease duration and response to other
biologic agents.Weaimed toevaluate responseofpatientswithCDorUC tovedolizumab, stratifiedby
disease duration.
METHODS: We analyzed data from a retrospective, multicenter, consortium of patients with CD (n[ 650) or UC
(n[ 437) treated with vedolizumab from May 2014 through December 2016. Using time to event
analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endo-
scopic remissionbetweenpatientswith early-stage (£2years duration) and later-stage (>2years) CD
or UC. We used Cox proportional hazards models to identify factors associated with outcomes.
RESULTS: Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of
patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR
(43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After
adjusting for disease-related factors including previous exposure to TNF antagonists, patients
with early-stage CD were significantly more likely than patients with later-stage CD to achieve
clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02–2.49), CSFR (aHR, 3.39; 95%
CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–3.39). In contrast, disease
duration was not a significant predictor of response among patients with UC.
CONCLUSIONS: Patients with CD for 2 years or less are significantly more likely to achieve a complete response,
CSFR, or endoscopic response to vedolizumab than patients with longer disease duration.
Disease duration does not associate with response vedolizumab in patients with UC.
Keywords: Inflammatory Bowel Disease; Integrin; Monoclonal Antibody Therapy; Time.
aAuthors share co-senior authorship.
Abbreviations used in this paper: aHR, adjusted hazard ratio; CD, Crohn’s
disease; CI, confidence interval; CSFR, corticosteroid-free remission; HR,
hazard ratio; IBD, inflammatory bowel disease; TNF, tumor necrosis fac-
tor; UC, ulcerative colitis.
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Crohn’s disease (CD) and ulcerative colitis (UC) areinflammatory bowel diseases (IBD) that result in
chronic inflammation of the gastrointestinal tract with
periods of remission alternating with relapse.1,2 It is
increasingly recognized that IBD, and CD in particular,
are progressive diseases in which patients accumulate
bowel damage over time that can lead to irreversible
complications.3–5 There seems to be an optimal window
of opportunity in which early effective intervention may
improve outcomes and alter the natural history of the
disease, akin to the evolving practice in rheumatoid
arthritis.6,7
Accumulating evidence suggests that treatment with
biologics targeting tumor necrosis factor (TNF)-a may be
more effective when initiated early in the disease course.
In a post hoc analysis of the PRECiSE 2 trial of certoli-
zumab in CD, patients with disease duration less than 2
years had an 82% response rate at 26 weeks, compared
with 59% among those with longer disease duration.8
Similar findings emerged from post hoc analyses of the
CHARM trial of adalimumab in CD, where higher clinical
remission rates at 56 weeks were seen among patients
with disease duration less than 2 years (43%) compared
with 2–5 years (30%) or greater than 5 years (28%),
even after controlling for potential confounding factors,
such as prior TNF antagonist exposure.9
Whether this treatment-modifying effect of early
disease duration is unique to the TNF antagonist drug
class or extends to other treatment agents (eg, anti-
integrins) is not clear. A post hoc analysis of the
ENCORE trial of natalizumab in CD found that disease
duration 3 years was associated with a higher pro-
portion of patients in clinical remission at 12 weeks than
the overall treatment population (52% vs 38%).10 No
studies published to date have evaluated response and
remission rates to vedolizumab stratified by disease
duration.
We aimed to evaluate the impact of disease duration
on vedolizumab effectiveness using a multicenter con-
sortium cohort study of the real-world experience with
vedolizumab. We analyzed rates of clinical and endo-
scopic remission in patients with CD and UC treated with
vedolizumab, comparing those with shorter disease
duration (2 years) with those with longer-standing (>2
years) disease.
Methods
Study Design
This is a retrospective review of the VICTORY Con-
sortium registry.11 In brief, this is a multicenter collab-
orative research group repository where outcomes are
pooled for patients with IBD treated with biologics.
Institutional review board approval was obtained from
each site for ongoing data collection and transfer. Data
were collected individually by sites using a standardized
data collection form and transferred (after deidentifica-
tion) to the coordinating site (University of California,
San Diego) for data compilation and analysis. The current
analysis represents data collected between May 2014
and December 2016. The results of this study are re-
ported in accordance with the Strengthening the
Reporting of Observational Studies in Epidemiology
guidelines for cohort studies.12
Variables
Data on variables of interest were collected including:
patient characteristics (age at diagnosis, age at vedoli-
zumab initiation, gender, smoking status, body mass in-
dex), disease characteristics (prior hospitalizations, prior
surgeries, disease-related complications or extra-
intestinal manifestations, and phenotype classified ac-
cording to the Montreal classifications for CD and UC),
and treatment history (steroids, immunomodulators, and
TNF antagonists; duration of use; indication for discon-
tinuation; and complications). Variables of interest spe-
cific to vedolizumab use were baseline disease severity
(endoscopic, radiographic, or clinical assessments),
concomitant treatments (steroids and/or immunomod-
ulators), infusions (dates, intervals, premedications), and
follow-up assessments (endoscopic, radiographic, or
clinical assessments). Clinical assessments were classi-
fied as severe versus nonsevere based on physician
What You Need to Know
Background
Patients with Crohn’s disease (CD), but not ulcerative
colitis (UC), of shorter duration have higher rates of
response to tumor necrosis factor antagonists than
patients with longer disease duration, but little is
known about the association between disease dura-
tion and response to other biologic agents. We
analyzed data from patients with CD or UC treated
with vedolizumab and used time to event analyses to
compare rates of clinical remission, corticosteroid-
free remission (CSFR), and endoscopic remission
between patients with early-stage (2 years dura-
tion) and later-stage (>2 years) CD or UC.
Findings
Patients with CD for 2 years or less were significantly
more likely to achieve a complete response, CSFR, or
endoscopic response to vedolizumab than patients
with longer disease duration. Disease duration did
not associate with response vedolizumab in patients
with UC.
Implications for patient care
Patients given a diagnosis of CD should begin treat-
ment with anti-TNF agent or vedolizumab as soon as
possible.
2498 Faleck et al Clinical Gastroenterology and Hepatology Vol. 17, No. 12
global assessment, where mild or moderate severity
were classified as nonsevere. The primary variable of
interest was disease duration, defined as a dichotomous
variable. Shorter duration was defined as 2 years and
longer duration as >2 years at the time of vedolizumab
initiation. This definition is consistent with most prior
data on the impact of disease duration on the efficacy of
biologics.8,9
Participants
Individuals were included in the current analysis if
they met the following criteria: (1) confirmed diagnosis
of CD or UC based on clinical and endoscopic or radio-
graphic data, (2) active clinical symptoms attributed to
CD or UC before starting vedolizumab, and (3) had at
least 1 clinical and/or endoscopic follow-up after initia-
tion of therapy. Patients started on vedolizumab for
indeterminate colitis or pouchitis, or those in clinical
remission at the time of starting vedolizumab (eg, pa-
tients with CD transitioned from natalizumab to vedoli-
zumab for safety or initiated on vedolizumab for
postoperative prophylaxis of CD) were excluded.
Outcomes
The primary outcomes of interest were the cumulative
rates for clinical remission, corticosteroid-free remission
(CSFR), or endoscopic remission at 6 months. Timing of
assessments for response followed routine practice stan-
dards as dictated by local sites with no predetermined or
standardized time-point of assessment. Clinical assess-
ments for remission were performed based on physician
global assessment, where remission was defined as com-
plete resolution of all CD- or UC-related symptoms by
treating physician evaluation. The assessment of CSFR
(performed only in patients on prednisone or budesonide
at the time of initiation of vedolizumab) was defined as
tapering off steroids completely, achieving clinical
remission, and no repeat steroid prescription within 4
weeks of tapering. Endoscopic remission was defined as
the absence of ulcers and/or erosions in CD or a Mayo
endoscopic score of 1 in UC.13,14 Endoscopic categori-
zation was done by local study investigators and was
reverified by a coordinating study investigator (P.S.D.)
using deidentified endoscopy reports, with any discrep-
ancies resolved through consensus between the study
sites and the coordinating site.
Statistical Analysis
Continuous variables were presented as means and
standard deviations, or as medians and interquartile
ranges based on data distribution. Categorical and binary
variables were presented as proportions or percentages.
For the comparison of baseline continuous variables, we
used the independent sample t test (2 group comparisons)
or 1-way analysis of variance with Bonferroni correction
(3 or more group comparisons). For the comparison of
baseline binary variables, we used the Pearson chi-square
or Fisher exact tests. Primary and secondary outcomes
were described quantitatively with Kaplan-Meier survival
and time-to-event analyses. Data were collected at clinical
follow-up times determined by each treating physician,
and 6-month cumulative outcomeswere used in this study
to maximize available data. A sensitivity analysis was
performed by transforming disease duration into a cate-
gorical variable (2 years, >2 years to 5 years, and >5
years), and outcomes were described quantitatively with
Kaplan-Meier survival and time-to-event analyses to un-
derstand if the definition for early disease in CD could be
extended to 5 years.
Cox proportional hazards regression analyses were
performed to identify independent predictors of treat-
ment outcomes. All baseline variables from the uni-
variable analyses with a P value of< .20 were fitted and a
backward model selection approach was taken where the
variablewith the highest P valuewas sequentially selected
out until all remaining variables in themodel had a P value
of< .05. Prior TNF antagonist exposurewas included in all
multivariable models, irrespective of P value. An assess-
ment of interaction terms was then performed and in-
teractions were retained if they had a P value of < .05.
Hazard ratios (HR) with 95% confidence interval (CI)
are presented for independent predictors where HR <1
indicated a predictor was associated with a reduced
probability for achieving the outcome and HR >1 indi-
cated a predictor was associated with an increased
probability for achieving the outcome. Two-sided P
values < .05 were considered statistically significant.
Statistical analyses were performed using Stata statistical
software (College Station, TX).
Study Sponsor
Takeda Pharmaceuticals provided funding for statis-
tical support to analyze the data. Takeda Pharmaceuti-
cals and associated employees did not have access to any
of the data, and all data analyses were performed at the
University of California San Diego by the VICTORY Con-
sortium investigators or statisticians.
Results
Crohn’s Disease: Demographics
A total of 650 patients with CDwere included. In the CD
group, there were significant differences in baseline dis-
ease and treatment-related characteristics between those
with disease duration 2 years and those with duration
greater than 2 years (Table 1). Patients with longer disease
duration had higher rates of CD-related complications
including stricturing and penetrating disease (70% and
38% vs 39% and 23%, respectively; P < .05 for both
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comparisons). A higher percentage of longer duration pa-
tients had failed TNF antagonists (77% vs 60%; P < .01),
and 70% of those in the longer disease duration group
previously had failed at least 2TNFantagonists versus34%
in the shorter disease duration group (P < .01).
Crohn’s Disease: Cumulative Rates and
Predictors of Remission
The cumulative rates for clinical remission, CSFR,
and endoscopic remission for CD at 6 months were
significantly higher in the early disease duration group
than in the longer disease duration group (Table 2,
Figure 1). When further stratifying the long disease
duration into >2 years to 5 years versus >5 years,
no differences were seen between these 2 groups
across any of the primary endpoints (Supplementary
Figure 1).
On multivariable analyses for CD, disease duration 2
years remained a significant predictor of clinical remis-
sion (adjusted HR [aHR], 1.59; 95% CI, 1.02–2.49), CSFR
(aHR, 3.39; 95% CI, 1.66–6.92), and endoscopic remis-
sion (aHR, 1.90; 95% CI, 1.06–3.39) (Table 3).
Ulcerative Colitis: Demographics
A total of 437 patients with UC were included. In
contrast to CD, there were few differences in baseline
demographic characteristics between the early and
longer disease duration of UC groups (Table 1). There
was a comparable distribution of disease extent ac-
cording to the Montreal classification between the 2
groups, a similar number of steroid-refractory or
steroid-dependent patients, and a comparable per-
centage of TNF antagonist naive patients (44% in both
groups). Notably, among those who had failed a prior
TNF antagonist, there was a higher percentage of in-
dividuals in the longer disease duration group who
had failed 2 or more TNF antagonist medications (25%
Table 1. Baseline Demographics of Patient Cohorts
CD UC
2 y (n ¼ 62) >2 y (n ¼ 588) P value 2 y (n ¼ 109) >2 y (n ¼ 328) P value
Age, y, median (IQR) 29 (23–44) 37 (27–52) .07 31 (24–52) 41 (29–57) < .01
Male, n (%) 29 (47) 243 (41) .42 57 (52) 161 (49) .58
CRP, median (IQR) 3.1 (1–10) 5 (1–18) .34 1.1 (0.4–5.4) 2.3 (0.7–7.8) .36
Albumin, median (IQR) 4.0 (3.6–4.3) 3.9 (3.6–4.2) .74 3.9 (3.6–4.3) 4.0 (3.7–4.3) .16
BMI, median (IQR) 23.7 (20–28.8) 23.7 (21–28.6) .71 23 (21.2–28) 25 (21.8–29) .86
Hospitalized in previous year, n (%) 32 (52) 203 (34) .01 28 (26) 82 (25) .90
CD phenotype, n (%)
Stricturing or penetrating disease 24 (39) 414 (70) < .01
Fistulizing disease 14 (23) 222 (38) .02
Prior surgery 22 (35) 377 (64) < .01
UC extent, n (%) .23
E1 4 (4) 18 (5)
E2 33 (30) 123 (38)
E3 72 (66) 187 (57)
Disease severity, severe, n (%) 21 (34) 202 (34) .53 42 (39) 98 (30) .06
Steroid refractory/dependent, n (%) 25 (40) 220 (37) .68 56 (51) 152 (46) .38
TNF antagonist failure, n (%) 37 (60) 455 (77) < .01 61 (56) 185 (56) 1.00
Number of prior TNF antagonist
agents, n (%)
< .01 .05
0 14 (23) 46 (8) 42 (38) 101 (31)
1 27 (44) 128 (22) 51 (47) 144 (44)
2þ 21 (34) 414 (70) 16 (15) 83 (25)
Concomitant steroids, n (%) 32 (52) 265 (45) .35 65 (60) 174 (53) .27
Concomitant IM, n (%) 19 (31) 251 (43) .08 44 (40) 103 (31) .10
BMI, body mass index; CD, Crohn’s disease; CRP, C-reactive protein; IM, immunomodulator; IQR, interquartile range; TNF, tumor necrosis factor; UC, ulcerative
colitis.
Table 2. Remission Rates at 6 Months Stratified by Disease
Duration
Remission rates
Crohn’s disease 2 y (n ¼ 62) >2 y (n ¼ 588)
Clinical remission, %a 38 23
Corticosteroid-free
remission, %a
43 14
Endoscopic healing, %a 29 13
Ulcerative colitis 2 y (n ¼ 109) >2 y (n ¼ 328)
Clinical remission, % 35 33
Corticosteroid-free
remission, %
22 20
Endoscopic healing, % 16 22
aSignificant (P < .05) on log-rank analyses.
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vs 15%; P ¼ .05) than in the shorter disease duration
group.
Ulcerative Colitis: Cumulative Rates and
Predictors of Remission
Among patients with UC, there were no significant
differences in any of the outcomes between those with
disease duration 2 years and those with longer disease
duration (Table 2). Univariable and multivariable
analyses were not performed for UC because initial time-
to-event analyses revealed no differences in outcomes
between early and longer disease duration groups.
Discussion
In this multicenter consortium study, we observed
that treatment with vedolizumab in the first 2 years after
diagnosis of CD is associated with higher rates of clinical,
corticosteroid-free, and endoscopic remission than
treatment initiated later in the disease course. This
improved treatment response was seen across all of the
study endpoints in CD, and persisted after controlling for
other predictors of treatment outcome, including prior
TNF antagonist therapy. In contrast, no association be-
tween disease duration and treatment outcome was seen
in patients with UC.
Figure 1. Cumulative rates of remission stratified by disease duration 2 years or >2 years. (A) Clinical remission. (B)
Corticosteroid-free remission. (C) Endoscopic remission.
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In recent years, there has been an intense interest in
early, aggressive treatment of CD, to reduce the long-
term morbidity associated with progressive bowel
damage.15 Early intervention is thought to target CD in a
“window of opportunity” before irreparable bowel
damage sets in.16 A lower percentage of patients in our
study in the early CD group had fistulizing or penetrating
complications, which supports this hypothesis. A second
theory invokes different immune responses in early
versus late CD,17 including differential T-cell immune
responses to interleukin-12 stimulation in children with
early versus late CD18 and increases in peripheral T-
helper cell type 17 cells in patients with late versus early
CD.19 Finally, the microbiome plays an important role in
responsiveness to therapy in IBD,20 and treatment-naive
early IBD may have a distinct microbiota composition
that can impact therapy outcomes.21
The landmark “Step-up/Top-down” study22 was the
first to show in a randomized controlled trial that early
aggressive therapy with combined infliximab and
azathioprine was superior to conventional step-up
approach in early CD for achieving early remission.
Similarly, a post hoc analysis of the landmark SONIC
trial23 stratifying by disease duration demonstrated
higher efficacy in achieving rigorous endpoints, such as a
composite of clinical remission, mucosal healing, and C-
reactive protein normalization in patients with CD
treated within 18 months of diagnosis.24 Similar findings
have been found with adalimumab and certolizumab
monotherapy in early CD.8,9 In contrast to TNF antago-
nist medications, immunomodulators have not been
shown to be more effective in early disease in achieving
remission and mucosal healing.25,26
Our data add to the growing literature on early inter-
vention in CD and demonstrate that improved outcomes
with early treatment are not a limited class effect of TNF
antagonist therapy. Importantly, this effect was seen even
in a relatively refractory cohort, with 60% of patients with
CD treated early with vedolizumab already having failed at
least 1 TNF antagonist. This finding represents an impor-
tant step in targeting disease modification in CD, because
vedolizumab has also been shown to have an excellent
safety profile,27,28 although studies with long-term follow-
up are still needed. Therefore, while balancing the benefits
of early intervention with the possible side effects of
increased duration of drug exposure, vedolizumab may be
an excellent candidate for early initiation.
In contrast to the emerging literature on the benefits
of early intervention in CD, there is a paucity of data on
early intervention in UC, and whether UC is a progressive
disease like CD remains unclear. In a retrospective
cohort study of the early initiation of infliximab or ada-
limumab within 3 years of UC diagnosis, Ma et al29 found
no difference in the rates of UC-related hospitalizations,
secondary loss of response, or colectomy between early
and late treatment groups. Similarly, Mandel et al30
found that early TNF antagonist use in CD, but not in
UC, was associated with decreased hospitalization rates.
We are also unaware of any post hoc analyses of clinical
trials in UC demonstrating any impact of disease dura-
tion on treatment efficacy. Our data are consistent with
these prior retrospective studies in showing no differ-
ence between early and late initiation of vedolizumab on
short-term treatment outcomes in UC.
The reason for the differing impact of early treatment
in UC versus CD is not clear. One hypothesis is that
Table 3.Multivariable Predictors of Treatment Outcomes in Crohn’s Disease
Predictors of treatment outcomes
in Crohn’s disease Unadjusted HR (95% CI) Adjusted HR (95% CI)
Clinical remission
Stricturing or penetrating phenotype 0.58 (0.44–0.77) 0.69 (0.51–0.92)
Disease severity (severe vs nonsevere) 0.40 (0.28–0.56) 0.53 (0.43–0.65)
Hospitalized in previous year 0.66 (0.49–0.90) 0.71 (0.52–0.97)
Disease duration 2 y 1.69 (1.09–2.61) 1.59 (1.02–2.49)
TNF antagonist exposure 0.51 (0.34–0.77) 0.64 (0.42–0.98)
Corticosteroid-free remission
Albumin 1.47 (0.89–2.43) 1.76 (1.04–2.97)
TNF antagonist exposure 0.43 (0.22–0.85) 0.40 (0.20–0.80)
Disease duration 2 y 2.99 (1.59–5.64) 3.39 (1.66–6.92)
Endoscopic remission
CRP 0.97 (0.96–0.99) 0.98 (0.96–0.99)
Albumin 2.29 (1.52–3.45) 1.70 (1.14–2.55)
Disease severity (severe vs nonsevere) 0.46 (0.32–0.66) 0.59 (0.45–0.77)
Disease duration 2 y 1.89 (1.12–3.18) 1.90 (1.06–3.39)
TNF antagonist exposure 0.63 (0.36–1.12) 0.95 (0.52–1.72)
NOTE. Variables entered in the multivariable models before backward selection was performed included those with P < .2. TNF antagonist exposure was included
in all models irrespective of P value at each step. For clinical remission, variables included gender, hospitalized within previous 1 year, CRP, albumin, structuring/
penetrating phenotype, fistulizing disease, disease severity, and concomitant steroids. For corticosteroid-free remission, variables included gender, CRP, albumin,
fistulizing disease, and disease severity. For endoscopic remission, variables included hospitalized within previous 1 year, CRP, albumin, structuring/penetrating
phenotype, fistulizing disease, disease severity, concomitant steroids, and combination therapy with immunomodulator.
CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; TNF, tumor necrosis factor.
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demonstration of disease modification in UC may require
a longer duration of follow-up. The risk of colorectal
malignancy has been shown to correlate with the in-
tensity and longevity of endoscopic and histologic in-
testinal inflammation,31 and therapy that can effectively
promote and maintain mucosal healing may decrease the
long-term risk of colorectal cancer.32–35 Histologic heal-
ing as an independent endpoint has garnered significant
attention in recent years36,37 and would be an interesting
endpoint for future evaluation in our cohort. Similarly,
chronic inflammation leading to bowel damage and
fibrosis in UC may yield poorer functional outcomes
because of loss of luminal wall compliance and devel-
opment of anorectal dysfunction and motility disor-
ders.32,38 Whether early intervention with vedolizumab
and other agents can alter the natural history of UC and
prevent these complications needs to be explored further
in longitudinal studies.
The strengths of our study include the large, real-
world, multicenter data set that represents a broad
population of individuals with IBD. Patients had detailed
clinical and endoscopic data collected using standardized
extraction methods. Our data are concordant with
studies of TNF antagonist medications in early IBD
showing a benefit in early CD but not UC, but importantly
we extend these findings to vedolizumab, which has not
previously been observed.
Our study does have several important limitations. The
retrospective collection of data across multiple in-
stitutions and the lack of well-validated clinical indices for
measuring treatment remission may impact response es-
timates. Additionally, no central reading of endoscopies
was performed, but rereview of reports by a single study
investigator resulted in <5% reclassification of endo-
scopic scoring. Furthermore, the follow-up time used for
the primary outcomes in this study was relatively short
and the rates of additional outcomes, such as surgeries
and hospitalizations, were too low for meaningful anal-
ysis. Further data collection is needed to assess the
durability of the improved response rates in the treatment
of early CD, and to assess for a possible impact on long-
term outcomes in UC. Finally, important differences exist
in the disease phenotype and treatment experience of the
early versus late groups, especially in CD. Despite rigorous
multivariable modeling to control for these factors, there
remains the possibility of unmeasured confounders
impacting response and remission rates.
In summary, we found that vedolizumab-treated pa-
tients with CD with early disease (2 years) had signif-
icantly improved outcomes with higher rates of clinical,
corticosteroid-free, and endoscopic remission than
those with longer disease duration. In contrast, this
improvement was not seen in patients with UC with
short disease duration treated with vedolizumab. The
combined safety and efficacy of vedolizumab makes it an
attractive candidate for early, aggressive intervention in
hopes of achieving lasting disease modification. Further
studies are needed to explore the impact of early use of
vedolizumab on long-term outcomes and its ability to
prevent disease progression in CD and UC.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://doi.org/10.1016/j.cgh.2018.12.040.
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Supplementary Figure 1. Cumulative rates of remission stratified by disease duration 2 years, >2 to 5 years, >5 years. (A)
Clinical remission (P ¼ .01 for 2 vs >5 years; P > .10 for all other comparisons). (B) Corticosteroid-free remission (P < .01 for
2 vs >5 years and P ¼ .02 for 2 vs >2 to 5 years; P > .10 for all other comparisons). (C) Endoscopic remission (P ¼ .02 for
2 vs >5 years and P ¼ .05 for 2 vs >2 to 5 years; P > .10 for all other comparisons).
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